New VEGF antagonists as possible therapeutic agents in vascular disease

Expert Opinion on Investigational Drugs

Volumn 17, Issue 9, 2008, Pages 1301-1314

  Slevin, M ^a,c   Kumar, P ^a   Wang, Quiyu ^a   Kumar, S ^b   Gaffney, J ^a   Grau Olivares, M ^d   Krupinski, J ^d  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c INST D INVESTIGACIONS B   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Atherosclerosis; Diabetic retinopathy; Nanotechnology; Tumour growth; Vascular endothelial growth factor

Indexed keywords

ADENOVIRUS VECTOR; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CETUXIMAB; DOCETAXEL; DOXORUBICIN; MACROGOL; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PEGAPTANIB; PLACEBO; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RECEPTOR BLOCKING AGENT; RUBOXISTAURIN; SMALL INTERFERING RNA; TG 100572; THROMBOCYTE GROWTH FACTOR ANTIBODY; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR BLOCKING AGENT; VINCA ALKALOID;

ANGIOGENESIS; ANTIANGIOGENIC GENE THERAPY; ATHEROSCLEROTIC PLAQUE; CANCER SURVIVAL; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CORNEA NEOVASCULARIZATION; DIABETIC RETINOPATHY; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; EYE DISEASE; GENE EXPRESSION REGULATION; GENE MUTATION; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NANOTECHNOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NONVIRAL GENE THERAPY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT DURATION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ATHEROSCLEROSIS; EYE DISEASES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 52949084355     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.9.1301     Document Type: Review

References (111)

1. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26:489-502
2. Shiba Y, Takahashi M, Ikedu U, Models for the study of angiogenesis. Curr Pharn Des 2008:14:371-7
3. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86
4. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
5. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80
6. McColl BK, Stacker SA, Achen MG. Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS 2004;112:463-80
7. Okada F, Rak JW, Croix BS, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular pertneability factor is necessary; but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998;95:3609-14
8. Tsuchiya N, Sato K, Akao T, et al. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohoku J Exp Med 2001;195:101-13
9. Liang D, Chang JR, Chin AJ, et al. The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development Mech Dev 2001; 108:29-43
10. Takahashi H, Shibuya M. The vascular indothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-41
11. Can Y, Linden, P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998;95:14389-94
12. Saharinen P Tammela T, Karkkinen MJ, et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation; Trends Immunol 2004;25:387-95
13. Ding S, Li C, Lin S, et al. Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep 2007;17:369-75
14. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology, Biochem Soc Trans 2003;31:1171-7
15. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39
16. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/ Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006;9:225-30
17. Yla-Herttuala S, Markkanen JE, Rissanen TT. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc Med 2004;14:295-300
18. Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007;4:181-9
19. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007;32:1-14
20. Wang ES, Turuya-Feldstein J, Wu, Y, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004;104:2893-902.
21. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61
22. Goldman CK, Kendall Cabrera G, et al. Parecrine expression of a native soluble vascular endothelial growth factor receptor inhibits, tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-800
23. Hussain S, Slevin M, Mesaik MA, et al. Cheiradone: a vascular endothelial cell growth factor receptor antagonist. BMC Cell Biol 2008;9:7
24. Wilkinson-Berka JL, Millar AG. Update on the treatment of diabetic retinopathy. Sci World J 2008;6:98-120
25. Sherris D. Ocular drug development future directions. Angiogenesis 2007; 10:71-6
26. McLeod D. A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage. Br J Ophthalmol 2007;91:677-89:
27. Le Goff MM, Bishop PN. Focus on molecules: opticin. Exp Eye Res 2007;85:303-4
28. Kakehashi A, Inoda S, Mameuda C, et al. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. Diabetes Res Clin Prac 2007;79:438-45
29. Ermakova NA, Syrodeeva ON, Antsiferov MB, et al. Role of vascular endothelial growth factor in the development of diabetic retinopathy in patients with type 1 diabetes mellitus. Vestn Oftalmol 2008;124:25-8
30. Hussain N, Ghanekar Y, Kanr I. The future implications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol 2007;55:445-50
31. Starita C, Patel M, Katz B, et al. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol 2007;39:122-48
32. Gragouclas ES, Adamis AP, Cunningham ET, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for age related macular degeneration. N Engl J Med 2004;351:2805-16
33. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular disease. Am J Ophthalmol 2006; 142:660-8
34. Campochiaro PA. Targeted pharmacotherapy of retinal diseases with ranibizumab Drugs Today 2007;43:529-37
35. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-8
36. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25
37. Sawada O, Kawamura H, Kakinoki M, et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125:1363-6
38. Amadio M, Scapagaini G, Lupo G, et al. PKCβII/HuR/VEGF: a new molecular cascade in retinal pericytes for the regulation of VEGF gene expression Pharmacol Res 2008;57:60-6
39. Idris I, Donnelly R. Protein kinase C beta inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diab Vasc Dis Res 2006;3:172-8.
40. Surace EM, Balaggan KS, Tessitore A. et al. Inhibition of ocular neovascularization by hedgehog blockade. Mol Ther 2006;13:573-9
41. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008;216:29-37
42. Palanki MS, Akiyama H, Campochiaro P, et al. Development of prodrug 4-chloro-3- (5-methyl-3- 4-(2-pyrrolidin-1-ylethoxy) phenyl] amino}-1,2,4-benzotriazin,in-7-yl) phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem 2008;51:1546-59
43. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signalling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-53
44. Shakiba Y, Mostafie A. Inhibition of corneal neovascularization with a nutrient mixture containing lysine, proline, ascorbic acid, and green tea extract. Arch Med Res 2007;38:789-91
45. Forooghian F, Das B. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. Am J Ophthalmol 2007; 144:761-8
46. Syonh MP, Lee FL, Kuo PC, et al. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol Vis 2007;13:133-41
47. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signalling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002;277-41046-59
48. Gunduz K, Bakri SJ. Management of proliferative diabetic retinopathy. Compr Ophthalmol Update 2007;8:245-56
49. Bradley J, Ju M, Robinsom GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007;10:141-8
50. Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears fi)r a new therapeutic strategy. Diabetologia 2008 [Epub ahead of print],
51. Simo F, Carrasco E, Garcia-Ramirez M, et al. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006;2:71-98
52. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
53. Jain RK Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
54. Jain RK. Taming vessels to treat cancer. Sci Am 2008;298:56-63
55. Rudge JS, Thurston G, Davis S, et al. VEGF trap as a novel anti-angiogenic treatment currently in clinical trials for cancer and eye diseases and VelociGene-based discovery of the next generation of angiogenesis targets in: molecular approaches to controlling cancer Cold Spr Harb Symp Quant Biol LXX Cold Spr Harb Lab Press: NY; 2006. p. 411-8
56. Duda DG, Batchelor TT, Willen CG, et al. VEGF targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30
57. Liang WC, WU X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281:951-61
58. Yang JC, Haworth L, Sherry AM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-734
59. Lee CG, Heijn M, Di Tomaso E, et al. Anti-vascular eadothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70
60. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001;98:4605-10
61. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
62. Mulay M, Limentani SA, Carroll M, et al. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumours [abstract]. Proc Am Soc Clin Oncol 2006;24
63. Horsman MR, Siemann DW. Pathophysiologic effect of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39
64. Tabenero J. The role of VEGF and, EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Ress 2007;5:203-20
65. Sun L, McMahon G. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov Today 2000;5:344-54
66. Wedge S, Jurgenmeister JM. VEGF receptor tyrosine kinase inhibitors for the treatment of cancer 'Tumour angiogenesis basic mechanisms and cancer theraphy'. In: Marine D, Fusenig N, editors, Springer; 2008. p. 395-423
67. Wood J, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and Potent inhibitor of vascular endothelial growth factor receptor kinases, impairs vascular endotheliual growth factor responses and tumour growth after oral administration. Cancer Res 2000;60:2178-89
68. Fong AT, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine-kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106
69. Stopeck A, Sheldon M, Vahedian M, et al. Results of phase I dose-escalating study of the anti-angiogenic agent, SU5416 in patients with advanced malignancies. Clin Cancer Res 2002;8:2798-805
70. Smolich B, Yuen D, West KA, et al. The anti-angiogenic protein kinase inhibitors SU5416 and SU6668 inhibits the SCF receptor (KIT) ina hunan myeloid leukaemia cell line and in acute myeloid leukaemia blasts. Blood 2001;97:1413-21
71. Beebe JS, Jani JP, Knauthe E, et al. Pharmacological characterisation of CP-547,632, a novel vascular endothelial growth factor receptor-2 throsine kinase inhibitor for cancer theraphy. Cancer Res 2003;63:7301-9
72. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small cell lung cancer. Clin Lung Cancer 2007;(Suppl 2);S79-85
73. Alfredez D, Wilkinson RW, Watkins J, et al. Dual inhibition of VEGFR and EGFR signalling reduces the incidence and size of intestinal adenornas in Ape (min/+) mice. Mol Cancer Ther 2008;7:590-8
74. Lokava M, Ya GN, Buzuk SM, et al. kliment'eva chemicai features of medicinal plants (review). Appl Biochem Microbiol 2001;37:229-37
75. Puerta-Fernandez E, Romero-Lopez C, Barroso Del Jesus A, et al. Ribozymes: recent advances and developments of RNA tools. FEMS Microbiol Rev 2003,27:75-97
76. Li LH, Gou ZJ, Yan LL, et al. Anti-tumor and antiangiogenic growth factor hairpin ribozymes target human hepatocellular carcinoma cell cultures and xenografts. World J Gastroenterol 2007;13:6425-32
77. Benezra R, Henke E, Ciarrocchi A, et al. Induction of complete regressions of oncogene- induced breast tumours in mice in: molecular approaches to controlling cancer. Cold Spr Harb Symp Quant Biol LXX Cold Spr Harb Lab Press: NY; 2005;volume 70 p. 375-81
78. Eichhorn ME, Strieth S, Luedemann S, et al. Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumour microcirculation in highly vascularized melanomas on short-term anti VEGFR treatment. Cancer Biol Ther 2008;7: [Epub ahead of print]
79. Szentirmai O, Baker CH, Bullain SS, et al. Successful inhibition of intracranial - glioblastoma multiforme xenograft growth via systemic adenovirai delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J Neurosurg 2008; 108:979-88
80. Murata N, Takashima Y, Toyoshima K, et al. Anti-tumour effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J Control Release 2008; 126:246-54
81. Wang Y, Saad M, Pakunlu RI, et al. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 (alpha) enhances the efficacy of chemotherapy in drug resistant tumor. Clin Cancer Res 2008;14:3607-16
82. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008;14:1540-9
83. Slevin M, Wang Q, Font MA, et al. Atherothrombosis and plaque heterology: different location or a unique disease? Pathobiology 2008;75:209-25
84. Khurana R, Simons M, Martin JF, et al. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005;112:1813-24
85. McCarthy MJ, Loftus IM, Thompson MM, et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999;30:261-8
86. Krupinski J, Font A, Luque A, et al. Angiogenesis and inflammation in carotid atherosclerosis. Front Biosci 2008;13:6472-82
87. Luque A, Turu M, Juan-Babot O, et al. Overexpression of hypoxia/ inflammatory markers in atherosclerotic carotid plaques. Front Biosci 2008;13:6483-90
88. Altaf N, MacSweeney ST, Gladman J, Auer DP. Carotid intraplaque hemorrhage predicts recurrent symptoms in patients with high-grade carotid stenosis. Stroke 2007;38:633-5
89. Simko F. Is NO king? Pathophysiological benefit with uncertain clinical impact. Physiol Res 2007;56:S1-6
90. Gudmundsdottir IJ, Lang NN, Boon NA, et al. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol 2008;51:1749-56
91. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9
92. Lutton A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by plgf treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-flt1. Nat Med 2002;8:831-40
93. Pels K, Labinaz M, Hoffert C, et al. Adventitial angiogenesis early after coronary angioplasty: correlation with arterial remodeling. Arterioscler Thromb Vasc Biol 1999;19:229-38
94. Pels K, Deiner C, Coupland SE, et al. Effect of adventitial vegf(165) gene transfer on vascular thickening after coronary artery balloon injury. Cardiovasc Res 2003;60:664-72
95. Celletti FL, Waugh JM, Amabile PG, et al. Inhibition of vascular endothelial growth factor-mediated neointima progression with angiostatin or paclitaxel. J Vasc Interv Radiol 2002;13:703-7
96. Ohtani K, Egashira K, Hiasa K, et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation 2004;110:2444-52
97. Laitinen M, Zachary I, Breier G, et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther 1997;8:1737-44
98. Khurana R, Shafi S, Martin J, Zachary I. Vascular endothelial growth factor gene transfer inhibits neointimal macrophage accumulation in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2004;24:1074-80
99. Li J, Post M, Volk R, et al. Pr39, a peptide regulator of angiogenesis. Nat Med 2000;6:49-55
100. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003;9:694-701
101. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-78
102. Ratner M. Genentech discloses safety concerns over avastin. Nat Biotechnol 2004;22:1198
103. Matsumoto T, Mugishima H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb 2006;13:130-5
104. Zeng G, Taylor SM, McColm JR, et al. Orientation of endothelial cell division is regulated by VEGF signalling during blood vessel formation. Blood 2007;109:1345-52
105. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischaemic heart disease: a phase 2 randomized, controlled trial of AdVEGF (121) versus maximum medical treatment. Gene Ther 2006;13:1503-11
106. Hao X, Silva EA, Mansson-Broberg A, et al. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Dis 2007;75:178-85
107. Kang SW, Lim HW, Seo SW, et al. Nanosphere-mediated delivery of vascular endothelial growth factor gene for therapeutic angiogenesis in mouse ischemic limbs. Biomaterials 2008;29:1109-17
108. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 2008;16:942-6
109. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis 2008;14:150-60
110. Birch DG, Liang FQ. Age-related macular degeneration: a target for nanotechnology derived medicines. Int J Nanomed 2007;2:65-77
111. Suri SS, Fenniri H, Singh B. Nanotechnology based drug delivery systems. J Occup Med Toxicol 2007;2:16